Logo

NanoString NCounter Vantage 3D Panels

Oct 19, 2016

NanoString Technologies has launched two new translational research assays, nCounter Vantage 3D DNA (SNV) Solid Tumor panel and nCounter Vantage 3D Protein Solid Tumor Signaling Pathways panel. The nCounter Vantage 3D DNA (SNV) Solid Tumor panel is designed for highly multiplexed profiling of known cancer mutations, as well as insertion and deletions from as little as five nanograms of DNA, while the nCounter Vantage 3D Solid Tumor Signaling Pathways panel enables the identification of activation state through the measurement of total proteins and phosphoproteins from a single slice of FFPE tissue or form as little as 250 ng of protein from cell or tissue lysate. The two new panels can be combined with one another as well as with the nCounter Vantage RNA panels to enable more comprehensive profiling of formalin-fixed, paraffin embedded tumor tissue.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.